Journal Article10.1161/circulationaha.114.010389
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica,Eugene Braunwald,Itamar Raz,Matthew A. Cavender,David A. Morrow,Petr Jarolim,Jacob A. Udell,Ofri Mosenzon,KyungAh Im,A. Umez-Eronini,Pia S. Pollack,Boaz Hirshberg,Robert Frederich,Basil S. Lewis,Darren K. McGuire,Jaime Davidson,P. Steg,Deepak L. Bhatt +17 more
74
TL;DR: In the context of balanced primary and secondary end points, saxagliptin treatment was associated with an increased risk or hospitalization for heart failure, and this increase in risk was highest among patients with elevated levels of natriuretic peptides, previousheart failure, or chronic kidney disease.
read more
About: This article is published in Circulation. The article was published on 28 Oct 2014.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi,Richard M. Bergenstal,John B. Buse,Michaela Diamant,Ele Ferrannini,Michael A. Nauck,Anne L. Peters,Apostolos Tsapas,Richard C. Wender,David R. Matthews +9 more
TL;DR: This briefer article should be read as an addendum to the previous full account on the management of hyperglycemia, which described the need to individualize both treatment targets and treatment strategies with an emphasis on patient-centered care and shared decision making.
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.
Janani Rangaswami,Vivek Bhalla,John E.A. Blair,Tara I. Chang,Salvatore P. Costa,Krista L. Lentine,Edgar V. Lerma,Kenechukwu Mezue,Mark E. Molitch,Wilfried Mullens,Claudio Ronco,W.H. Wilson Tang,Peter A. McCullough +12 more
TL;DR: The mission of this scientific statement is to describe the epidemiology and pathogenesis of cardiorenal syndrome in the context of the continuously evolving nature of its clinicopathological description over the past decade.
924
Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary.
Alan J. Garber,Martin J. Abrahamson,Joshua I. Barzilay,Lawrence Blonde,Zachary T. Bloomgarden,Michael A. Bush,Samuel Dagogo-Jack,Ralph A. DeFronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey R. Garber,W. Timothy Garvey,George Grunberger,Yehuda Handelsman,Robert R. Henry,Irl B. Hirsch,Paul S. Jellinger,Janet B. McGill,Jeffrey I. Mechanick,Paul D. Rosenblit,Guillermo E. Umpierrez +20 more
TL;DR: This chapter discusses the development and use of eicosapentaenoic acid as a treatment for diabetic ketoacidosis and its applications in conventional and regenerative medicine.
801
JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure ― Digest Version ―
Hiroyuki Tsutsui,Mitsuaki Isobe,Hiroshi Ito,Ken Okumura,Minoru Ono,Masafumi Kitakaze,Koichiro Kinugawa,Yasuki Kihara,Yoichi Goto,Issei Komuro,Yoshikatsu Saiki,Yoshihiko Saito,Yasushi Sakata,Naoki Sato,Yoshiki Sawa,Akira Shiose,Wataru Shimizu,Hiroaki Shimokawa,Yoshihiko Seino,Koichi Node,Taiki Higo,Atsushi Hirayama,Miyuki Makaya,Tohru Masuyama,Toyoaki Murohara,Shin-ichi Momomura,Masafumi Yano,Kenji Yamazaki,Kazuhiro Yamamoto,Tsutomu Yoshikawa,Michihiro Yoshimura,Masatoshi Akiyama,Toshihisa Anzai,Shiro Ishihara,Takayuki Inomata,Teruhiko Imamura,Yu-ki Iwasaki,Tomohito Ohtani,Katsuya Onishi,Takatoshi Kasai,Mahoto Kato,Makoto Kawai,Yoshiharu Kinugasa,Shintaro Kinugawa,Toru Kuratani,Shigeki Kobayashi,Yasuhiko Sakata,Atsushi Tanaka,Koichi Toda,Takashi Noda,Kotaro Nochioka,Masaru Hatano,Takayuki Hidaka,Takeo Fujino,Shigeru Makita,Osamu Yamaguchi,Uichi Ikeda,Takeshi Kimura,Shun Kohsaka,Masami Kosuge,Masakazu Yamagishi,Akira Yamashina +61 more
TL;DR: This English language document is a revised digest version of Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (JCS 2017/JHFS 2017) reported at the Japanese Circulation Society Joint Working Groups performed in 2017.
Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
TL;DR: The mechanisms underlying the development of diabetic cardiomyopathy and heart failure in type 1 and type 2 diabetes mellitus are discussed, the evidence from preclinical and clinical studies are summarized, and signalling pathways that might be potential therapeutic targets are described.
570
References
•Journal Article
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R C Turner,C Fox,Matthews,H McElroy,Carole A. Cull,Rury R. Holman,P. A. Neil,D R Hadden,D Wright,E Manley,Irene M Stratton,UK Prospective Diabetes,E M Kohner,Frighi,Michael Gnant +14 more
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
13.8K
•Journal Article
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
R C Turner,Rury R. Holman,Irene M Stratton,Carole A. Cull,David R Matthews,Susan E. Manley,V Frighi,D Wright,Andrew Neil,E M Kohner,H McElroy,C Fox,D R Hadden,Grp Ukpds. +13 more
TL;DR: Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
8.4K
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
4.3K
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica,Deepak L. Bhatt,Deepak L. Bhatt,Eugene Braunwald,P. Gabriel Steg,Jaime A. Davidson,Boaz Hirshberg,Peter Öhman,Robert Frederich,Stephen D. Wiviott,Elaine B. Hoffman,Matthew A. Cavender,Jacob A. Udell,Nihar R. Desai,Ofri Mosenzon,Darren K. McGuire,Kausik K. Ray,Lawrence A. Leiter,Itamar Raz +18 more
TL;DR: Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased.